Abstract
186Re is considered as “Therapy” Isotope and can be used in radioimmunotherapy. The radiation characteristics of this isotope are ideal for therapy. Generally metallic radionuclides are labeled to antibodies through bifunctional chelating agents, such as DTPA (diethylenetetraaminepentaacetic acid). A study has been carried out on the complexation of DTPA with186Re using low specific activity186Re. This was carried out to evaluate various parameters which are involved in the complex formation including methods of processing of raw material186Re. Stannous chloride was used as the reducing agent for the reduction of rhenium. Different labeling conditions such as pH, time, temperature and concentration of reducing agent were all studied for complex formation. The complex was characterized by paper electrophoresis, paper chromatography and gel column chromatography.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Radioanalytical and Nuclear Chemistry Articles
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
